Stryker Q1 - Steady Growth

Medical device-maker Stryker has been a Vestact-recommended stock since January 2014. In that time they've made good progress, growing sales from around $10 billion a year to $18 billion. Profits have risen steadily too, and so has the share price.

Second-quarter earnings released last week were better than expected, resulting in a modest share price rally.

Our best guess is that humans will continue to spend more money in years to come on hip and knee replacements, spinal surgeries and other hospital procedures. Stryker's robotic surgery division, called Mako, will continue to thrive. Humans are living longer, and have medical insurance to cover these high-cost outlays.

We expect more good things from this company. The delays in elective surgeries created by Covid are being overcome. They remain innovative, developing facilities like this one (pictured below) in Ireland for 3D printing medical devices.

Stryker is one of our "future heroes", a company that has a market cap of only $80 billion but could grow much larger in time.